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Successful Therapy of Lethal Murine Visceral Leishmaniasis
with Cystatin Involves Up-Regulation of Nitric Oxide and a
Favorable T Cell Response1
Lopamudra Das, Neeta Datta, Santu Bandyopadhyay, and Pijush K. Das2
The virulence of Leishmania donovani in mammals depends at least in part on cysteine proteases because they play a key role in
CD41 T cell differentiation. A 6-fold increase in NO production was observed with 0.5 mM chicken cystatin, a natural cysteine
protease inhibitor, in IFN-g-activated macrophages. In a 45-day BALB/c mouse model of visceral leishmaniasis, complete elim-
ination of spleen parasite burden was achieved by cystatin in synergistic activation with a suboptimal dose of IFN-g. In contrast
to the case with promastigotes, cystatin and IFN-g inhibited the growth of amastigotes in macrophages. Although in vitro cystatin
treatment of macrophages did not induce any NO generation, significantly enhanced amounts of NO were generated by macro-
phages of cystatin-treated animals. Their splenocytes secreted soluble factors required for the induction of NO biosynthesis, and
the increased NO production was paralleled by a concomitant increase in antileishmanial activity. Moreover, splenocyte super-
natants treated with anti-IFN-g or anti-TNF-a Abs suppressed inducible NO generation, whereas i.v. administration of these
anticytokine Abs along with combined therapy reversed protection against infection. mRNA expression and flow cytometric
analysis of infected spleen cells suggested that cystatin and IFN-g treatment, in addition to greatly reducing parasite numbers,
resulted in reduced levels of IL-4 but increased levels of IL-12 and inducible NO synthase. Not only was this treatment curative
when administered 15 days postinfection, but it also imparted resistance to reinfection. These studies provide a promising alter-
native for protection against leishmaniasis with a switch of CD41 differentiation from Th2 to Th1, indicative of long-term
resistance. The Journal of Immunology, 2001, 166: 4020–4028.
I nfection with the flagellated protozoan Leishmania is a majorhealth problem with significant morbidity and mortality inthe tropics and subtropics. Over 350 million people live in
areas where the disease is common, and large epidemics affecting
hundreds of thousands have occurred as recently as 1991 (1).
Leishmania donovani, the etiological agent for the severe visceral
form of leishmaniasis known as kala azar in humans, multiplies in
the phagolysosomes of macrophages of the infected host. At
present, there is no satisfactory, widely available vaccine against
leishmaniasis, and chemotherapy remains the major medical mode
of managing the disease. However, the existing drugs used against
leishmaniasis, such as antimonials, pentamidine, and amphotericin
B, are highly toxic, have serious side effects, and elicit drug re-
sistance (2). Compounding these problems is the fact that many
countries and regions where the disease is endemic are economi-
cally poor. Limitations of this nature have undoubtedly necessi-
tated the current drive to develop and produce effective therapy
against all forms of leishmanial infection, particularly the fatal
visceral form.
An attractive target for new therapy is a family of cathepsin
L-like and cathepsin B-like cysteine proteases, found in all species
of Leishmania examined and required for parasite growth and vir-
ulence (3, 4). Elimination of cathepsin L-like gene families by
homologous recombination resulted in loss of virulence in highly
susceptible BALB/c mice (3, 4), whereas deletion of the cathepsin
B-like gene led to reduced survival of parasites in macrophages (3,
5). Therefore, it was thought worthwhile to investigate the possible
role of cystatin, a natural cysteine protease inhibitor, in modulating
L. donovani infection. However, one major complicating factor in
chemotherapeutic treatment is the depressed immune functions ex-
hibited by the victims of disseminated leishmaniasis. Appropriate
T cell-mediated responses are of primary importance in an effec-
tive host defense in visceral leishmaniasis (6). There is also a cor-
relation between host control over parasite replication and the
activation of Th1-type effector cells that produce the macrophage-
activating cytokines IFN-g and IL-2 (7). Both in humans (8, 9) and
in experimental animal models (10, 11), L. donovani infection is
accompanied by parasite-specific immune depression mediated by
T cells and macrophages, thereby preventing spontaneous cure and
the development of protective immunity. Moreover, nonhealing
infections in susceptible strains of mice such as BALB/c are ac-
companied by the preferential expansion of IL-4-producing Th2-
type cells (12). Therefore, immunostimulation of the infected host
is an effective strategy for circumventing immunosuppression.
IFN-g could be used as an immunopotentiator for augmenting the
capacity of macrophages to eliminate Leishmania infection. More-
over, the safety of parenteral human rIFN-g has been demonstrated
for various diseases, including leprosy, cancer, and AIDS (13–15).
However, IFN-g treatment alone is not sufficient to promote a Th1
response and/or suppress in vivo activation of Th2 cells because
even continued IFN-g therapy has little effect on the eventual out-
come of a Leishmania major infection in BALB/c mice (16).
Studies to date suggest that the parasite cysteine proteases may
themselves help to ensure a Th2-like response in BALB/c mice
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that leads to parasite proliferation (17). Thus, inhibition of such
cysteine proteases might slow or even prevent parasite prolifera-
tion and allow the host immune system to function effectively and
confer protective immunity by effecting a switch in CD41 T cell
differentiation from Th2 to Th1 (18). Tight binding and reversible
natural inhibitors that belong to the cystatin superfamily regulate
cysteine proteases. Experiments have revealed that chicken cysta-
tin, the best-characterized inhibitor of cysteine proteases (19, 20),
stimulated NO (3) production by IFN-g-activated macrophages
(21). Because NO is the key effector molecule for antileishmanial
activity, we tested the capacity of cystatin to elicit a Th1-mediated
adaptive response and to prevent and treat infections with L. do-
novani, a lethal Th2-mediated disease, in BALB/c mice. Our in-
vestigation was aimed toward elucidating the dual role of cystatin
in suppressing the functional differentiation of Th2-type CD41 T
cells and in turn augmenting Th1 response, together with the abil-
ity to up-regulate NO, the latter property being totally unrelated to
the former. Here we present data demonstrating that cystatin can
synergize with subthreshold concentrations of IFN-g in inducing
Th2-Th1 conversion and generation of NO, resulting in abrogation
of parasite infection.
Materials and Methods
Parasites and Ag
L. donovani strain AG83 (MHOM/IN/1983/AG83) was isolated from an
Indian patient with kala azar (22). The strain was maintained in BALB/c
mice by i.v. passage every 6 wk. L. donovani promastigotes for use in
experiments were obtained by allowing isolated splenic amastigotes to
transform in parasite growth medium for 72 h at 22°C. The growth medium
consisted of medium 199 (Life Technologies, Grand Island, NY) supple-
mented with 10% (v/v) FCS. Soluble leishmanial Ag (SLA)3 was prepared
from promastigotes by freeze-thawing the cell suspension (5 3 109
cells/ml in 100 mM Tris-HCl, pH 8.0, containing 1 mM EDTA, 50 mg/ml
leupeptin, and 1.6 mM PMSF) three to five times followed by sonication
for 5 3 45 s at 20 kilocycles/min in an ice bath. The contents were cen-
trifuged at 10,000 3 g for 20 min, and the supernatant was dialyzed, fil-
tered, and stored at 270°C. It was used at a concentration of 20 mg/ml.
Macrophages
Macrophages were collected by peritoneal lavage from mice (BALB/c;
20–25 g) given i.p. injection of 0.5 ml 4% thioglycolate broth 5 days before
harvest and were used as described earlier (23). The culture medium con-
sisted of RPMI 1640 supplemented with 10 mM HEPES, 100 U/ml peni-
cillin, 100 mg/ml streptomycin, and 10% FCS. A total of .90% of the cell
preparation was identified as macrophages by microscopic observation, and
the macrophages were routinely found to be .95% viable by trypan blue
exclusion.
Splenocyte culture
Spleens were aseptically removed and teased into single-cell suspensions
in RPMI 1640 supplemented with penicillin (100 U/ml), streptomycin (100
mg/ml), 2-ME (50 mM), L-glutamine (2 mM), HEPES (10 mM), and 10%
(v/v) FCS (24). RBCs were removed by lysis with 0.83% (w/v) NH4Cl.
The remaining cells were washed twice with culture medium, and the vi-
able mononuclear cell number was determined by counting trypan blue-
unstained cells in a hemocytometer. Splenocyte suspensions (1 3 106 cells/
ml) were dispensed into 35-mm tissue culture plates and incubated at 37°C
in 5% CO2 for 48 h. Cells were harvested for RT-PCR and flow cytometric
analysis. Culture supernatants were removed and frozen at 220°C until
further use.
In vitro L. donovani proliferation assay
Promastigotes of L. donovani were cultured in medium 199 containing
10% (v/v) FCS with or without chicken cystatin (egg white, E2801% 5 8.7;
Sigma, St. Louis, MO) and IFN-g for 72 h at 22°C. The proliferation of
promastigotes was evaluated by counting them every 24 h in a
hemocytometer.
In vitro assay of L. donovani growth in macrophages
Promastigotes were used to infect cultures of adherent macrophages on
glass cover slips (18 mm2; 5 3 105 macrophages/cover slip) in 0.5 ml of
RPMI 1640/10% FCS at a ratio of 10 parasites/macrophage. Infection was
allowed to proceed for 4 h, unphagocytosed parasites were removed by
washing with medium, and cells were resuspended in RPMI 1640/10%
FCS with or without chicken cystatin and IFN-g, along with each compo-
nent added alone, for 48 h at 37°C. Cells were then fixed in methanol and
stained with Giemsa stain for determination of intracellular parasite num-
bers. The mean percentages of survival in treated cultures were calculated
on the basis of considering the number of Leishmania in untreated cultures
as 100%.
Determination of NO concentration
NO, quantified by the accumulation of nitrite in the culture medium, was
measured according to the method of Ding et al. (25). Briefly, 100 ml of
culture supernatants was mixed with an equal volume of Griess reagent
(1% sulfanilamide and 0.1% N-(1-naphthyl)ethylenediamine dihydrochlo-
ride in 2.5% H3PO4) and incubated at room temperature for 10 min. Ab-
sorbance at 540 nm was then measured. Sodium nitrite (NaNO2) diluted in
culture medium was used as a standard.
Establishment and assessment of infection
Mice were inoculated with L. donovani AG83 through the tail vein. Ini-
tially, 107 promastigotes/mouse were injected, and for reinfection the same
number of promastigotes was injected 60 days after the first infection. At
1 and 15 days after inoculation of parasites, cystatin, either alone or in
combination with a suboptimal dose of IFN-g (104 U), was injected into the
tail vein in various doses for 4 consecutive days. Forty-five days after the
start of infection, animals were sacrificed, and their spleens were weighed.
Multiple spleen impression smears were prepared and stained with Giemsa
stain. Spleen parasite burdens, expressed as Leishman-Donovan units
(LDU), were calculated as the number of amastigotes per 1000 nucleated
cells 3 spleen weight (grams) (26).
RT-PCR analysis of cytokine mRNA
RT-PCR was performed to determine the cytokine profile of mRNA for
IL-12 p40, IL-4, inducible NO synthase (iNOS), and hypoxanthine phos-
phoribosyltransferase (HPRT). Reverse transcription of 1 mg of RNA was
performed according to the manufacturer’s protocol for the Superscript
One-Step RT-PCR system (Life Technologies). The primers for all these
genes have been published (27). After the appropriate number of PCR
cycles, the amplified cDNA was separated by 2% agarose gel electrophore-
sis and visualized by ethidium bromide staining.
Flow cytometric analysis
Mice were infected with L. donovani (107 parasites/mouse) and treated
with cystatin plus IFN-g 15 days after infection. For intracellular IL-4
staining, splenocytes were isolated 45 days postinfection, plated aseptically
(1 3 106 cells/ml), and stimulated with SLA (20 mg/ml) for 48 h, whereas
for IL-12 p40 staining, purified splenic macrophages were stimulated like-
wise. Cells were incubated with monensin (Sigma) (2 mM) for 4 h, washed
in PBS containing 0.1% NaN3/1% FCS at 4°C, and fixed with paraformal-
dehyde. They were then permeabilized with saponin and treated with PE-
conjugated anti-mouse IL-12 p40 and IL-4 mAbs. Cells were analyzed on
a FACSCalibur cytofluorometer using the CellQuest software (BD Bio-
sciences, San Jose, CA). The area of positivity was determined using an
isotype-matched mAb.
Statistical analysis
The significance of the data was evaluated by the two-tailed t test.
Results
Up-regulation of nitrite production in mouse peritoneal
macrophages by cystatin and IFN-g
To determine whether chicken cystatin, a natural inhibitor of cys-
teine proteases, could modulate the infection of macrophages by L.
donovani and NO synthesis, macrophages were subjected to treat-
ment with various agents (Fig. 1). Neither cystatin (0.5 mM) nor
IFN-g (100 U/ml) when added alone could induce marked pro-
duction of nitrite after 48 h of incubation (1.51 6 0.23 nmol/106
cells and 3.32 6 0.35 nmol/106 cells, respectively). However, the
3 Abbreviations used in this paper: SLA, soluble leishmanial Ag; iNOS, inducible NO
synthase; HPRT, hypoxanthine phosphoribosyl transferase; NMMA, NG-monometh-
yl-L-arginine; LDU, Leishman-Donovan units.
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nitrite level was significantly increased (6-fold) when cystatin was
added simultaneously with IFN-g, as compared with IFN-g alone.
Moreover, although L. donovani infection caused a suppression of
NO production in IFN-g-activated macrophages (1.12 6 0.17
nmol/106 cells), combined treatment of infected macrophages with
cystatin and IFN-g for 48 h produced 12.18 6 1.24 nmol NO22/
106 cells. The up-regulation of NO by cystatin in IFN-g-stimulated
macrophages was not due to the presence of LPS as a contaminant
because preincubation of cystatin with polymyxin B, an LPS in-
hibitor, did not alter NO production. However, the NO-inducing
effect in the control experiment, consisting of LPS preincubated
with polymyxin B, was completely abolished.
Effect of cystatin and IFN-g on the progression of leishmaniasis
Because cystatin together with IFN-g can up-regulate NO, the ef-
fector molecule responsible for antileishmanial activity, it was
thought worthwhile to evaluate the efficacy of the combination
chemotherapy in a BALB/c mouse model of visceral leishmania-
sis. BALB/c mice (6 wk old, ;20 g) were infected i.v. with L.
donovani AG83 promastigotes as described in Materials and
Methods. The infection was allowed to proceed for 45 days, during
which spleen weight increased from 100.46 6 11.17 mg to
1650.16 6 139.92 mg. Two types of drug treatment schedule were
chosen, one at the onset of infection and the other at established
infection. IFN-g or cystatin or a combination of both were admin-
istered i.v. daily for 4 consecutive days beginning 1 day after in-
fection (onset of infection) and 15 days after infection (established
infection). Various cystatin dosages were used (from 0.1 to 10
mg/kg/day), with a constant dose of 104 U of IFN-g per mouse.
Three i.p. injections of .105 U IFN-g alone, given every other
day, halted the visceral replication of L. donovani (7); however,
treatment with four injections of 104 U produced only modest in-
hibition and no killing (7). Therefore, a dose of 104 U IFN-g was
selected to use in combination with cystatin. All animals were
sacrificed 45 days after inoculation, and the degree of leishmani-
cidal potency of cystatin or IFN-g or both was assessed in terms of
spleen weight and splenic amastigote burden. The combination
therapy with cystatin and IFN-g was found to be much more potent
than either component in terms of 100% parasite suppression. In
the case of both onset of infection and established infection, a dose
of 5 mg/kg/day of cystatin together with 104 U IFN-g per mouse
given for 4 days greatly reduced and possibly eliminated all par-
asites from the spleen, with subsequent reduction in its weight to
nearly normal levels (Fig. 2). Absence of parasites in the spleen
was further confirmed by culturing spleen specimens in transfor-
mation medium at 22°C for 96 h. Cystatin or IFN-g alone at the
same dose had little effect.
Effect of cystatin and IFN-g on the growth of promastigotes
To ascertain the possibility that cystatin along with IFN-g might
exert a direct cytotoxic effect on L. donovani, the influence of the
combination regimen on the in vitro proliferation of L. donovani
promastigotes was assessed (Fig. 3). L. donovani proliferated com-
parably regardless of the presence or absence of cystatin and
IFN-g in the growth medium.
FIGURE 1. NO production by mouse peritoneal macrophages subjected
to treatment with various agents. Macrophages (106/ml) were incubated for
48 h in culture medium with cystatin (5 3 1027 M), L. donovani (mac-
rophage:parasite, 1:10), IFN-g (100 U/ml), IFN-g plus L. donovani, IFN-g
plus cystatin plus L. donovani, IFN-g plus cystatin, IFN-g plus cystatin
plus polymyxin B preincubation (10 U/ml for 2 h), IFN-g 1 LPS (1 mg/
ml), and IFN-g plus LPS plus polymyxin B preincubation. Data represent
the mean 6 SD of three experiments.
FIGURE 2. Schematic representation of experimental protocol for treat-
ment of L. donovani-infected BALB/c mice. Mice were infected with 1 3
107 L. donovani promastigotes. A, Days 1–4, treatment at onset of infec-
tion; day 8, first appearance of amastigotes in the spleen; days 15–18,
treatment at established infection; day 45, sacrifice. B, Reduction in the
weight of spleen after treatment with IFN-g (104 U) and cystatin (5 mg/
kg/day). a, Normal untreated; b, infected untreated; and c, infected treated.
C and D, Suppression of spleen parasites by cystatin and cystatin plus
IFN-g. Cystatin at the indicated doses was administered daily for 4 con-
secutive days, 1 day (C) and 15 days (D) after infection. The log10 LDU of
infected controls was 2.49 6 0.04 in C and 2.48 6 0.03 in D, whereas those
of the IFN-g (104 U)-treated group were 2.29 6 0.04 and 2.41 6 0.02 in
C and D, respectively. All data are mean log10 LDU 6 SD of five mice.
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Effect of combined therapy on amastigote proliferation
To assess the effects of combination treatment on L. donovani
amastigotes, the inhibition of amastigote multiplication within
macrophages by IFN-g and cystatin was compared with that of
either component given alone. Leishmania-infected cultures were
treated with cystatin or IFN-g or both for 48 h at 37°C in macro-
phage culture medium. Controls were placed in medium alone.
After drug treatment, cells were washed and placed in drug-free
medium for an additional 20 h. They were then stained, and viable
parasites per macrophage were counted. It is difficult to differen-
tiate viable from nonviable amastigotes immediately after treat-
ment. Therefore, a 20-h interval between drug treatment and stain-
ing was chosen to allow for the disposal of dead parasites.
Combination IFN-g and cystatin treatment was most effective with
an IC50 of 4.3 mg/ml for cystatin, whereas cystatin alone had no
inhibitory effect (Fig. 4A). To test whether reactive NO is involved
in the growth inhibition of amastigotes, we used the specific NO
synthase inhibitor, NG-monomethyl-L-arginine (NMMA). Com-
plete reversal of antileishmanial effect was observed upon the ad-
dition of NMMA (Fig. 4A). Moreover, NO22 release by macro-
phages treated with a suboptimal dose of IFN-g (100 U/ml)
progressively increased with increasing cystatin concentration un-
til 1 mM, when it reached a maximum level (Fig. 4B). In contrast,
cystatin when added to macrophage culture alone was unable to
induce any NO production. There was no toxic effect from cystatin
on macrophages in vitro at the highest concentration used for treat-
ment. Therefore, these results suggest that increased antileishma-
nial activity after combination treatment with IFN-g and cystatin
may be correlated with increased production of NO.
Effect of in vivo administration of cystatin on NO up-regulation
Because cystatin was unable to induce any NO production in peri-
toneal macrophages, we set about to determine whether the gen-
eration of NO by macrophages isolated from cystatin-treated mice
also corroborated their in vitro effect. Peritoneal macrophages iso-
lated from BALB/c mice given i.v. injections of cystatin produced
significantly higher levels of NO22 (13.02 6 1.56 nmol/106 cells)
compared with control untreated counterparts (1.20 6 0.18 nmol/
FIGURE 3. Effect of cystatin and IFN-g on growth
of L. donovani promastigotes. Varying concentrations
of cystatin were used, whereas the concentration of
IFN-g was fixed at 100 U/ml. L. donovani promas-
tigotes were cultured in medium 199 containing 10%
FCS and were counted at 24-h intervals using a light
microscope.
FIGURE 4. Effect of cystatin and IFN-g on amastigote proliferation and
NO production in mouse peritoneal macrophages. A, Infected macrophages
were treated with various concentrations of cystatin either alone or in com-
bination with IFN-g (100 U/ml) for 48 h at 37°C. In another set of exper-
iments, NMMA (2.5 mM) was used along with cystatin and IFN-g. Infected
control and IFN-g-treated cultures contained 7.14 6 0.67 and 6.38 6 0.52
amastigotes/macrophage, respectively. B, Dose-response curves of various
concentrations of cystatin for the release of NO22 by macrophages treated
with or without IFN-g (100 U/ml). Data are mean 6 SD of three
experiments.
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106 cells; p , 0.001; Fig. 5A). These cells also inhibited the rep-
lication of L. donovani (Fig. 5B). NMMA, the NO synthase inhib-
itor, was found to reverse the stimulatory effect of cystatin.
Moreover, macrophages isolated from BALB/c mice given i.v. ad-
ministration of 5 mg/kg/day cystatin and 104 U IFN-g produced
much higher levels of NO22 (27.50 6 2.47 nmol/106 cells) com-
pared with their in vitro counterparts (12.18 6 1.24 nmol/106 cells;
p , 0.001; Fig. 5A). The level of nitrite produced by various reg-
imens was reflected in the expression of iNOS mRNA, which, after
isolation of total RNA, was subjected to RT-PCR analysis as de-
scribed in Materials and Methods (Fig. 5C).
The role of cytokines in the in vivo activation by cystatin
To look into the mechanism of regulation of NO in the in vivo
situation, spleen cells were isolated from mice given i.v. injections
of cystatin. It was found that the generation of NO by peritoneal
macrophages from control untreated mice was increased after cul-
turing them in supernatants of splenocytes obtained from cystatin-
administered animals (12.10 6 1.10 compared with 1.20 6 0.18
nmol/106 cells; Fig. 6). The increase in NO production was par-
alleled by an increase in the antileishmanial activity of these cells
(Fig. 6). Splenocyte supernatant from mice treated with both cys-
tatin and IFN-g had a considerably stronger effect on NO produc-
tion by virgin macrophages (data not shown). In an effort to de-
termine the involvement of specific cytokines in the in vivo
activation of macrophages by cystatin, peritoneal macrophages
from untreated mice were cultured in splenocyte supernatants ob-
tained from either cystatin-treated or PBS-treated mice in the pres-
ence or absence of mAbs against various cytokines. It was found
that the addition of either anti-IFN-g or anti-TNF-a greatly re-
duced the ex vivo NO22 production as well as the antileishmanial
activity (Fig. 6). No detectable levels of nitrite were found in
splenocyte supernatants. To further ascertain the roles of IFN-g
and TNF-a in vivo, mice were i.v. administered 5 mg/kg/day of
cystatin alone or in combination with 200 mg of anti-IFN-g, anti-
TNF-a, or control hamster IgG at the onset of infection. Spleen
parasite burden was then determined 45 days after infection (Table
I). Anticytokine mAbs reactive against either IFN-g or TNF-a
greatly reduced cystatin-mediated protection, whereas the parasite
load in mice treated with cystatin plus control Abs was similar to
that in mice treated with cystatin alone. As an additional control,
neutralizing mAbs to other cytokines, IL-1a, IL-1b, and IL-6,
were also examined. However, these cytokines were ineffective in
stimulating NO production by macrophages in culture (Fig. 6), and
administration of mAbs against these cytokines had little effect on
cystatin protection.
Cytokine production in treated mice
To gain an insight into the levels of various cytokines and iNOS
after combination chemotherapy, we examined the flow cytometric
pattern as well as the mRNA expression for a Th1 cytokine (e.g.,
IL-12), a Th2 cytokine (e.g., IL-4), and iNOS, which catalyzes the
generation of NO from L-arginine and mediates the leishmanicidal
activity of treated macrophages. Because both the treatment pro-
tocols (onset of infection as well as established infection) for com-
bined therapy resulted in almost complete suppression of spleen
parasite burden, we selected the therapeutic treatment of IFN-g
and cystatin (15 days after injection) for the measurement of cy-
tokines. RT-PCR analysis of cytokine mRNA levels confirmed that
susceptible BALB/c mice treated with a combined dose of IFN-g
FIGURE 5. Generation of NO (A) and intracellular
proliferation of L. donovani (B) in peritoneal macro-
phages after treatment of mice with cystatin or IFN-g or
both. Mice received i.v. injections of either cystatin (5
mg/kg/day) or IFN-g (104 U/mouse) or both for 4 con-
secutive days. Peritoneal macrophages were harvested
10 h after the last injection and infected with L. dono-
vani. After a 4-h infection and a 20-h incubation period,
the percentage of parasite suppression and the amount of
NO22 in the medium, which serves as a measure of NO,
were determined. The nature of iNOS expression was
also determined by RT-PCR of its mRNA transcript (C).
In the case of inhibition experiments, the NO inhibitor,
NMMA (5 mM), was coinjected with cystatin and was
also present in the culture medium of macrophages. Val-
ues are the means of three experiments; error bars indi-
cate the SDs.
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and cystatin could reverse an established Th2 response into a dom-
inant Th1 response (Fig. 7A). Thus, Leishmania-infected cells
from mice treated with IFN-g and cystatin contained more IL-12
p40 mRNA and less IL-4 mRNA than those from infected un-
treated controls. Mice treated with either component alone at that
dose exhibited little amounts of IL-12 p40 mRNA, although ad-
ministration of cystatin alone showed some increase over untreated
ones. Similarly, mice treated with both IFN-g and cystatin also had
low levels of parasite-specific IgG1, a Th2-associated isotype, but
higher levels of parasite-specific IgG2a (data not shown). In ad-
dition, the iNOS mRNA expression, which was very low in the
spleen cells of L. donovani-infected mice, was significantly in-
duced by the combined therapy of IFN-g and cystatin.
The effect of combination chemotherapy on the production of
IL-12 p40 and IL-4 was determined by flow cytometric analysis of
spleen cells isolated from infected BALB/c mice in the presence or
absence of cystatin and IFN-g. For this, splenocytes and purified
macrophages were separately stimulated in vitro with SLA and
permeabilized, and a one-color flow cytometry for IL-12 p40 and
IL-4, respectively, was performed. Results reveal that a higher
frequency of cells from mice subjected to combination chemother-
apy (9.13%; Fig. 7Be) produced IL-12 p40 compared with un-
treated ones, in which the intracellular IL-4 status in CD41 T cells
was 14.24% (Fig. 7Bh). Moreover, mice treated with cystatin pro-
duced more IL-12 p40 and less IL-4 than those treated with a
suboptimal dose of IFN-g. These results suggest that Th2 functions
have been effectively suppressed in BALB/c mice by combination
chemotherapy so that Th1 function could be activated sufficiently
to resolve infection with L. donovani.
Reinfection with L. donovani in BALB/c mice treated with
cystatin and IFN-g
To further ascertain that the combination regimen has conferred
long-standing immunity, infected BALB/c mice treated with cys-
tatin and IFN-g were later reinfected i.v. 60 days after primary
infection. Spleen parasite burden in the reinfected animals pro-
gressed prominently in PBS-treated BALB/c mice, whereas cys-
tatin- and IFN-g-treated mice were largely resistant, as observed
up to 7 wk (Fig. 8). Thus, infected BALB/c mice subjected to a
combination chemotherapy with cystatin (5 mg/kg/day) and a sub-
optimal dose of IFN-g (104 U/mouse) acquired protective
immunity.
Discussion
Papain family cysteine proteases occur in abundance in trypano-
somes and Leishmania and are believed to play key roles in par-
asite-host interactions including establishment of infection (28).
The present study has demonstrated that BALB/c mice with fatal
visceral leishmaniasis can be clinically cured of the disease by
chicken cystatin, a natural cysteine protease inhibitor, in synergy
with IFN-g. The impetus for this combination chemotherapy was
the earlier observation that cystatin could up-regulate NO release
from IFN-g-activated macrophages (21). NO produced by cyto-
kine-activated macrophages during parasite infections is known to
play a central role in the control of parasite killing (29). That the
mice treated with cystatin and a suboptimal dose of IFN-g were
indeed cured was shown by the reversion of spleen size to near-
normal levels and the complete suppression of spleen parasite bur-
den. Moreover, this therapy was effective in mice with ongoing
infections in which a nonprotective Th2 response had been estab-
lished. After treatment and the resulting resolution of parasitism,
the cytokine profile in these mice indicated a switch to a protective
Th1 pattern. Treatment with either component alone had very little
effect. The superior efficacy of the combination treatment in elim-
inating intracellular amastigotes of L. donovani in both an in vitro
macrophage model and an in vivo mouse model of visceral leish-
maniasis demonstrated the effectiveness of this approach. Neither
the components nor the dosage used proved toxic to macrophages,
as evidenced by their viability (trypan blue exclusion) and the
release of lactate dehydrogenase from cells (data not shown). Dur-
ing the experimental period, all the animals remained healthy,
without any apparent weight loss.
Increased microbicidal activity of cystatin- and IFN-g-activated
macrophages is achieved by a nitrogen-dependent mechanism. En-
hanced NO generation resulted upon incubating cystatin with IFN-
g-activated mouse peritoneal macrophages in vitro, and the leish-
manicidal activity acquired correlated with the induction of NO
production. It may be mentioned that Engel et al. (30) showed a
FIGURE 6. Effect of anticytokine mAbs on NO production and intra-
cellular parasite suppression in peritoneal macrophages grown in spleno-
cyte supernatant from cystatin-treated mice. Peritoneal macrophages har-
vested from untreated mice (5 3 105 cells/18 mm2 cover slips) were grown
for 24 h in supernatants of splenocytes isolated from mice treated with
cystatin (four i.v. injections, 5 mg/kg/day). Macrophages were cultured in
splenocyte supernatants either alone or in the presence of 20 mg of each of
the anticytokine mAbs and were infected with L. donovani. After a 4-h
infection and a 20-h incubation period, the percentage of parasite suppres-
sion (M) and the amount of NO22 in the medium (o) were determined. The
number of amastigotes per macrophage and the amount of NO22 generated
in infected controls cultured in splenocyte supernatants of PBS-treated
mice were 4.53 6 0.10 and 1.26 6 0.18 nmol/106 cells, respectively. Val-
ues are means of three experiments; error bars indicate SDs.
Table I. Effect of anticytokine mAbs on parasite suppression in
infected mice
Treatment Groupa
Spleen Parasite
Burden (LDU)
% Parasite
Suppression
L. donovani-infected mice
treated with:
PBS alone 306.9 6 31.0 (4)b 0
Cystatin 52.0 6 6.3 (3) 83.1
Cys 1 anti-IFN-g 187.1 6 16.7p (3) 39.0
Cys 1 anti-TNF-a 152.0 6 19.9p (3) 48.1
Cys 1 anti-IL-1a 63.8 6 5.4 (3) 79.2
Cys 1 anti-IL-1b 61.4 6 8.4 (3) 80.0
Cys 1 anti-IL-6 74.1 6 5.9 (3) 75.9
Cys 1 Control IgG 64.6 6 7.0 (3) 78.9
a Infected mice were administered i.v. cystatin (5 mg/kg/day) for 4 consecutive
days 1 day after infection. On day 4, mice were injected with 200 mg of mAbs to
IFN-g, TNF-a, IL-1a, IL-1b, IL-6, or hamster IgG (control Ab). Spleen parasite
burden was determined 45 days after infection and expressed as LDU.
b Numbers in parentheses represent the number of mice.
p, p , 0.001 compared with cystatin treatment groups.
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parasiticidal effect of synthetic cysteine protease inhibitors on in-
tracellular Trypanosoma cruzi by inactivation of cruzain, a major
protease of the parasite. The reason cystatin may induce an in-
crease in NO synthesis from activated macrophages remains un-
clear. However, it is known that the biological effect of cystatin as
a synergic NO inducer is not related to the inhibition of cysteine
protease activity because the irreversible and structurally unrelated
cysteine protease inhibitor E64 did not induce any increase in ni-
trite level (21). Also, from the structural standpoint, the observa-
tion that saturation of cystatin-inhibitory sites by reduced-alky-
lated papain did not interfere with cystatin-induced NO release
from activated macrophages suggests the noninvolvement of in-
hibitory sites in the process (21). Although our in vitro studies
demonstrated the inability of cystatin alone to induce NO synthesis
in macrophages, our in vivo studies argue against this. Thus, cys-
tatin given in vivo induced NO synthesis in peritoneal macro-
phages, along with an enhancement of inhibition of parasite
growth. This suggests that NO generation by macrophages may be
an indirect effect of cystatin activation requiring the cooperation of
macrophages and other cells of the immune system. The ability of
cystatin to induce NO in synergy with IFN-g in vitro is suggestive
of the compensatory role of IFN-g for the effector molecules of
immune system cells. Therefore, protection against infections with
L. donovani induced by i.v. administration of cystatin and IFN-g
correlated with the development of activated macrophages secret-
ing NO. Moreover, strong evidence for the participation of both
IFN-g and TNF-a in cystatin regulation of NO production and
protection against leishmaniasis in vivo was suggested by the ob-
servation that anti-IFN-g or anti-TNF-a mAbs could effectively
block the significant increase in NO production by normal un-
treated macrophages when activated with the splenocyte superna-
tant from cystatin-treated mice. Further, the in vivo administration
of anti-IFN-g or anti-TNF-a mAbs could block the induction of
cystatin-mediated protection against L. donovani infection. The
immunologic stimulus for the production of cytotoxic levels of NO
in vitro by murine macrophages is the synergistic effect of IFN-g
FIGURE 7. Induction of Th1-phenotype in L. donovani-infected mice sub-
jected to combination chemotherapy as analyzed by (A) RT-PCR and (B) flow
cytometry. A, Expression of IL-4, IL-12, iNOS, and HPRT mRNA by spleen
cells of infected mice treated i.v. with either cystatin or IFN-g or both. RT-
PCR products were visualized by ethidium bromide staining. RNA samples
were obtained from three mice in each group. Results are representative of
three separate samples. HPRT expression levels were used as controls for
RNA content and integrity. B, Expression of intracellular IL-12 p40 and IL-4
by splenic macrophages and lymphocytes after in vitro stimulation with SLA.
Cells were permeabilized and stained with anti-mouse IL-12 p40-PE, IL-4-PE,
and isotype-matched control rat Ab and were analyzed by flow cytometry.
FIGURE 8. Course of reinfection with L. donovani in mice previously
treated with curative doses of IFN-g and cystatin. Naive age-matched
BALB/c mice and cured mice (IFN-g plus cystatin-treated) were i.v. ad-
ministered with 1 3 107 promastigotes of L. donovani through the tail vein.
The progression of infection was monitored by determining the spleen
parasite burden, expressed as LDU, up to 7 wk after reinfection.
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and exogenous TNF or microbes and microbial products to stim-
ulate endogenous release of TNF-a by macrophages (31–34). Ex-
ogenous agent-stimulated TNF acts in an autocrine fashion to am-
plify the actual synthesis and release of NO by IFN-g-primed cells
(33, 35). The data obtained with anti-IFN-g and anti-TNF-a mAbs
in cystatin-treated mice suggest that a similar synergism exists in
vivo. It is likely that the in vivo administration of cystatin stimu-
lates TNF synthesis, which in turn triggers IFN-g production by
spleen lymphocytes. Therefore, IFN-g and TNF-a are the principal
agents in macrophage activation by cystatin in vivo, and the pro-
tection afforded by combined treatment against experimental vis-
ceral leishmaniasis ultimately depended on the physiologic gener-
ation of NO. Indeed, cystatin has been shown very recently to
cause production of increased amounts of TNF-a in IFN-g-primed
macrophages (36). Because LPS alone can induce NO production,
we examined the effect of the LPS inhibitor polymyxin B and
confirmed that the LPS contamination of cystatin used was insuf-
ficient to induce NO production from macrophages.
Several studies have emphasized the importance of Th1 cyto-
kines in host defense mechanisms against infection caused by var-
ious microbial pathogens (37). Some insight as to how therapy
with IFN-g and cystatin influences the production of various cy-
tokines and macrophage NO was gained by examination of mRNA
levels and flow cytometric analysis of spleen cells 45 days after
infection. Transcript levels of IL-4 were reduced in mice given
combined therapy, whereas those for iNOS and IL-12 p40 were
significantly elevated. Flow cytometric analysis of cells secreting
cytokines also corroborated the mRNA transcript results. Because
IL-4 can suppress both NO and IL-12 p40 production, it is possible
that a reduction in the IL-4 level after combined treatment may
assist IFN-g in promoting both macrophage NO and IL-12 pro-
duction. In contrast, IL-12 induces IFN-g production and cytotoxic
activity by NK and T cells (38) and can initiate the differentiation
of Th1 cells from naive T cells (39–41). IL-12 enhances IFN-g
production by Th1 clones (42) and promotes the proliferation of
Th1 but not Th2 cells (39). However, because IFN-g can prime
macrophages to produce IL-12 p40 (43), it is possible that the
administration of exogenous IFN-g as done in this study acts as a
positive stimulus for enhanced IL-12 production, which in turn
may promote both higher IFN-g production and Th1 cell
development.
Taken together, the findings in this report support the view that
a complex series of cytokines and cell-mediated interactions con-
tributes to the host’s innate response to visceral leishmaniasis. The
stimulatory capacity of cystatin may also confound studies involv-
ing site-specific targeting for enhanced macrophage activation.
The absence of any host cell or animal toxicity at therapeutic doses
suggests that the parasites are more susceptible to inhibitor, per-
haps because of the redundancy of cysteine proteases in mamma-
lian cells vs the parasite. It may be mentioned that administration
of a cathepsin B-specific inhibitor to highly susceptible BALB/c
mice resulted in a switch from the usual inefficient Th2 cytokine
response to a Th1 response that cleared the L. major infection (18).
In contrast, the administration of vinyl sulfone inhibitor, an irre-
versible cysteine protease inhibitor, to a mouse model of cutaneous
leishmaniasis did not result in a switch from Th2 to Th1 cytokines.
It exerted its antileishmanial effect by inhibiting parasite replica-
tion (44). In the present study, cure as well as resistance acquired
by susceptible BALB/c mice due to combination chemotherapy
were attributed to two mechanisms: 1) the direct action of cystatin
for the induction of the NO that kills the parasite; and 2) the switch
of CD41 T cell-mediated immune responses from the disease-
promoting Th2 to the protective Th1 type. The switching of an
established inappropriate Th response to an appropriate one has
implications not only for the treatment of nonhealing leishmaniasis
but also for the treatment of other chronic infectious diseases.
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